The bill
Stop Chinese Fentanyl Act of 2025
HR. 747, 119th Congress — read as touching Pharmaceuticals.
Sponsored by
Rep. Barr, Andy [R-KY-6]
ID: B001282
Follow the money
The bill
HR. 747, 119th Congress — read as touching Pharmaceuticals.
The sponsor
Every bill has someone who introduced it. That name is where the paper trail starts.
The money
22 itemised contributions to this sponsor, pulled from FEC filings.
Track this bill's progress through the legislative process
Latest Action
Received in the Senate and Read twice and referred to the Committee on Banking, Housing, and Urban Affairs.
September 2, 2025
📍 Current Status
Next: Both chambers must agree on the same version of the bill.
1. Introduction: A member of Congress introduces a bill in either the House or Senate.
2. Committee Review: The bill is sent to relevant committees for study, hearings, and revisions.
3. Floor Action: If approved by committee, the bill goes to the full chamber for debate and voting.
4. Other Chamber: If passed, the bill moves to the other chamber (House or Senate) for the same process.
5. Conference: If both chambers pass different versions, a conference committee reconciles the differences.
6. Presidential Action: The President can sign the bill into law, veto it, or take no action.
7. Became Law: If signed (or if Congress overrides a veto), the bill becomes law!
Another brilliant example of Congressional theater, designed to make the masses feel like something is being done about the opioid crisis while actually accomplishing nothing.
**Main Purpose & Objectives:** The Stop Chinese Fentanyl Act of 2025 is a masterclass in legislative posturing. Its primary objective is to appear tough on China and the opioid epidemic while doing little to address the root causes of either issue. The bill's sponsors want you to believe they're taking bold action, but it's all just a show.
**Key Provisions & Changes to Existing Law:** The bill amends the Fentanyl Sanctions Act to include Chinese entities that produce or traffic fentanyl precursors. It also expands the definition of "foreign opioid trafficker" to include senior Chinese officials who allegedly aid and abet trafficking. But don't be fooled – these changes are largely symbolic, as they rely on the President's discretion to enforce sanctions.
The bill also modifies the International Emergency Economic Powers Act to require periodic evaluations of the effectiveness of economic sanctions related to national emergencies, including those related to international drug trafficking. Because, you know, Congress loves to create more paperwork and bureaucratic hurdles.
**Affected Parties & Stakeholders:** The usual suspects are affected by this bill:
* Chinese entities involved in fentanyl production or trafficking (but only if they're unlucky enough to get caught) * Senior Chinese officials who might be deemed "foreign opioid traffickers" (good luck with that) * The President, who gets to decide whether to enforce sanctions * Congressional committees, which will receive periodic evaluations and reports (yawn)
**Potential Impact & Implications:** This bill is a Band-Aid on a bullet wound. It won't significantly impact the flow of fentanyl into the United States or address the underlying causes of addiction. Instead, it will create more red tape, bureaucratic delays, and opportunities for corruption.
The real winners are:
* Lobbyists who pushed for this legislation * Politicians who get to grandstand about being tough on China and opioids * The Chinese government, which will likely just find ways to circumvent the new regulations
In conclusion, HR 747 is a textbook example of legislative malpractice. It's a feel-good bill designed to appease voters while accomplishing nothing meaningful. If you're looking for real solutions to the opioid crisis, keep looking – this isn't it.
Rep. Barr, Andy [R-KY-6]
Congress 119 • 2024 Election Cycle
No PAC contributions found
No committee contributions found
This bill has 9 cosponsors. Below are their top campaign contributors.
ID: N000193
Top Contributors
10
ID: M001210
Top Contributors
10
ID: L000599
Top Contributors
10
ID: M001236
Top Contributors
10
ID: K000397
Top Contributors
10
ID: L000596
Top Contributors
0
No contribution data available
ID: B001327
Top Contributors
10
ID: P000614
Top Contributors
10
ID: G000602
Top Contributors
10
Hub layout: Politicians in center, donors arranged by type in rings around them.
Showing 65 nodes and 37 connections (48 secondary connections hidden)
Total contributions: $164,854
Showing top 21 donors by contribution amount
Which industries are materially affected by specific provisions in this bill. 2 harmed.
Section 3 amends the Fentanyl Sanctions Act to include entities that produce or distribute opioid precursors, which could impact pharmaceutical companies involved in such activities.
Section 2 Sense of Congress mentions working with the US Government to identify unregulated chemicals used for precursor production, potentially affecting biotech firms involved in such research